Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.

Item

http://www.wikidata.org/entity/Q47162004

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.

@en

Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.

@nl

type

Item

label

Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.

@en

Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.

@nl

prefLabel

Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.

@en

Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.

@nl

P1476

Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.

@en

P2093

Esteban Celis

http://www.w3.org/2001/XMLSchema#string

Hiroya Kobayashi

http://www.w3.org/2001/XMLSchema#string

Hussein Sultan

http://www.w3.org/2001/XMLSchema#string

Hyun-Il Cho

http://www.w3.org/2001/XMLSchema#string

Sujin Lee

http://www.w3.org/2001/XMLSchema#string

Takumi Kumai

http://www.w3.org/2001/XMLSchema#string

Yasuaki Harabuchi

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor-specific Th17-polarized cells eradicate large established melanoma

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells

Comparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responses

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

T helper lymphocytes rescue CTL from activation-induced cell death.

Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

P304

72-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-16-0194

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27941004

http://www.w3.org/2001/XMLSchema#string

P932

5221568

http://www.w3.org/2001/XMLSchema#string